Efficacy and Safety of Insuman Basal/Comb/Rapid in Patients With Type 2 Diabetes
Status:
Completed
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
Primary Objective:
- To evaluate the decrease of Hb A1c ≥ 1% after 6 month treatment in patients with Type 2
Diabetes Mellitus (T2DM) uncontrolled on Oral Antidiabetics (OADs)
Secondary Objectives:
- To evaluate the percentage of patients with Hb A1c < 7.5%,
- To evaluate the rate of hypoglycaemia (symptomatic, severe)
- To evaluate the middle dose of insulin per product - Insuman Basal, Insuman Comb,
Insuman Rapid after 6 month treatment
- To evaluate the change in Fasting Plasma Glucose (FPG) after 6 month treatment
- To assess the overall safety
- To evaluate the efficacy of education courses in Diabetes Schools (% of correct answers
after second test compare to the testing of the initial level)